Application of Semi-Markov Process For Model Incremental Change in HIV Staging with Cost Effect
DOI:
https://doi.org/10.6000/1929-6029.2022.11.12Keywords:
HIV, Semi-Markov, Cost-effectiveness, Sojourn time, Viral loadAbstract
In the recent past, both non-parametric and parametric approaches have consistently been used to model cost effectiveness in a variety of health applications. This study applies the semi-Markov model while presenting the sojourn time with well-defined probability distributions. We employed the Weibull distribution to model the hazard function for each of the defined transition paths. We defined three distinct states of the semi-Markov process using the quantity of HIV virus in the blood of an HIV-infected person i.e., viral load (VL) copies in a milliliter (copies/mL). The three states were defined; VL < 200 copies/mL, 200 copies/mL < VL < 1,000 copies/mL, VL > 1,000 copies/mL and an absorbing state which is naturally death. We also developed a cumulative cost function, purposely to determine the average estimated cost per patient in each of the defined states. Incremental Cost Effectiveness Ratio (ICER) was utilized in the analysis of cost-effectiveness while comparing two program strategies i.e., Patients under the differentiated care model (DCM) and those who are not considered to be in any model of differentiated care during their respective ongoing clinical follow up. Results show the mean cost of the patients for each state 1, 2, and 3 was $765, $ 829, and $ 1,395 respectively. More so, the computed ICER ratio was $ 484/life-year-saved. In conclusion, the cost of keeping patients in state 1 (on DCM) was relatively cheaper and more efficient compared to the other states.
References
UNAIDS. UN joint programme on HIV/AIDS (UNAIDS). Trends of new HIV infections. Geneva: UNAIDS, 2020.
WHO. Programmatic update: Antiretroviral treatment as prevention (tasp) of HIV and TB: executive summary. World Health Organization, 2012.
UNAIDS. Prevention gap report: Joint united nations programme on HIV/AIDS. Geneva: UNAIDS, 2016.
Kates J, Wexler A, Lief E, et al. Donor Government funding for HIV in low and middle-income countries in 2019. Menlo Park, CA: The Henry J Kaiser Family Foundation & UNAIDS, 2019.
Hillis A, Maguire M, Hawkins BS, Newhouse MM. The Markov process as a general method for nonparametric analysis of right-censored medical data. Journal of Chronic Diseases 1986; 39: 595-604. https://doi.org/10.1016/0021-9681(86)90184-0 DOI: https://doi.org/10.1016/0021-9681(86)90184-0
Kryscio RJ, Abner EL, Lin Y, Cooper GE, Fardo DW, Jicha GA, et al. Adjusting for mortality when identifying risk factors for transitions to mild cognitive impairment and dementia. Journal of Alzheimer’s Disease 2013; 35: 823-832. https://doi.org/10.3233/JAD-122146 DOI: https://doi.org/10.3233/JAD-122146
Salazar JC, Schmitt FA, Yu L, Mendiondo MM, Kryscio RJ. Shared random effects analysis of multi-state markov models: application to a longitudinal study of transitions to dementia. Statistics in Medicine 2007; 26: 568-580. https://doi.org/10.1002/sim.2437 DOI: https://doi.org/10.1002/sim.2437
Abner EL, Charnigo RJ, Kryscio RJ. Markov chains and semi-markov Models in time-to-event analysis. Journal of Biometrics & Biostatistics 2013; p. 19522.
Sonnenberg FA, Beck JR. Markov models in medical decision making: A practical guide. Medical Decision Making 1993; 13: 322-338. https://doi.org/10.1177/0272989X9301300409 DOI: https://doi.org/10.1177/0272989X9301300409
Kang M, Lagakos SW. Statistical methods for panel data from a semi-markov process, with application to HPV. Biostatistics 2007; 8: 252-264. https://doi.org/10.1093/biostatistics/kxl006 DOI: https://doi.org/10.1093/biostatistics/kxl006
UNAIDS. Kenya AIDS response progress report 2018. Kenya: UNAIDS, 2018.
Marseille E, Kahn JG, Pitter C, Bunnell R, Epalatai W, Jawe E, Were W, Mermin J. The cost effectiveness of home-based provision of Antiretroviral therapy in rural Uganda. Applied Health Economics and Health Policy 2009; 7: 229-243. https://doi.org/10.1007/BF03256157 DOI: https://doi.org/10.1007/BF03256157
Castelli C, Combescure C, Foucher Y, Daures J-P. Cost-effectiveness analysis in colorectal cancer using a semi-markov model. Statistics in Medicine 2007; 26(30): 5557-5571. https://doi.org/10.1002/sim.3112 DOI: https://doi.org/10.1002/sim.3112
Goshu AT, Dessie ZG. Modelling progression of HIV/AIDS disease stages using semi-markov processes. Journal of Data Science 2013; 11: 269-280. https://doi.org/10.6339/JDS.201304_11(2).0004 DOI: https://doi.org/10.6339/JDS.201304_11(2).0004
Mengesha SK, Gebremedhn GA, Ferede T, Atsmegiorgis C. Application of multi-state semi-markov models on HIV/AIDS disease progression. i-Manager's Journal on Mathematics 2018; 7: 30. https://doi.org/10.26634/jmat.7.3.14988 DOI: https://doi.org/10.26634/jmat.7.3.14988
Liu L, Wolfe RA, Kalbfleisch JD. A shared random effects model for censored medical costs and mortality. Statistics in Medicine 2007; 26: 139-155. https://doi.org/10.1002/sim.2535 DOI: https://doi.org/10.1002/sim.2535
Portet S. A primer on model selection using the akaike information criterion. Infectious Disease Modelling 2020; 111-128. https://doi.org/10.1016/j.idm.2019.12.010 DOI: https://doi.org/10.1016/j.idm.2019.12.010
Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. Journal of the American Medical Association 1996; 276: 1253-1258. https://doi.org/10.1001/jama.1996.03540150055031 DOI: https://doi.org/10.1001/jama.276.15.1253
Chambers JD, Cangelosi MJ, Neumann PJ. Medicare’s use of cost-effectiveness analysis for prevention (but not for treatment). Health Policy 2015; 119(2): 156-163. https://doi.org/10.1016/j.healthpol.2014.11.012 DOI: https://doi.org/10.1016/j.healthpol.2014.11.012
Willan AR, Lin D, Manca A. Regression methods for cost-effectiveness analysis with censored data. Statistics in Medicine 2005; 24: 131-145. https://doi.org/10.1002/sim.1794 DOI: https://doi.org/10.1002/sim.1794
Foucher Y, Mathieu E, Saint-Pierre P, Durand J-F, Daur`es J-P. A semi-markov model based on generalized weibull distribution with an illustration for HIV desease. Biometrical Journal: Journal of Mathematical Methods in Biosciences 2005; 47(6): 825-833. https://doi.org/10.1002/bimj.200410170 DOI: https://doi.org/10.1002/bimj.200410170
Song C, Kuo L, Derby CA, Lipton RB, Hall CB. Multi-stage transitional models with random effects and their application to the Einstein aging study. Biometrical Journal 2011; 53: 938-955. https://doi.org/10.1002/bimj.200900259 DOI: https://doi.org/10.1002/bimj.200900259
Gardiner JC, Luo Z, Bradley CJ, Sirbu CM, Given CW. A dynamic model for estimating changes in health status and costs. Statistics in Medicine 2006a; 25(21): 3648-3667. https://doi.org/10.1002/sim.2484 DOI: https://doi.org/10.1002/sim.2484
Cohen DJ, Reynolds MR. Interpreting the results of cost-effectiveness studies. Journal of the American College of Cardiology 2008; 52(25): 2119-2126. https://doi.org/10.1016/j.jacc.2008.09.018 DOI: https://doi.org/10.1016/j.jacc.2008.09.018
Lin D, Feuer E, Etzioni R, Wax Y. Estimating medical costs from incomplete follow-up data. Biometrics 1997; pp. 419-434. https://doi.org/10.2307/2533947 DOI: https://doi.org/10.2307/2533947
Austin PC, Ghali WA, Tu JV. A comparison of several regression models for analysing cost of cabg surgery. Statistics in Medicine 2003; 22(17): 2799-2815. https://doi.org/10.1002/sim.1442 DOI: https://doi.org/10.1002/sim.1442
Gardiner JC, Luo Z, Liu L, Bradley CJ. A stochastic framework for estimation of summary measures in cost–effectiveness analyses. Expert Review of Pharmacoeconomics & Outcomes Research 2006b; 6: 347-358. https://doi.org/10.1586/14737167.6.3.347 DOI: https://doi.org/10.1586/14737167.6.3.347
Akaike H. Fitting autoregressive models for prediction. Annals of the Institute 1969; 21(1): 243-247. https://doi.org/10.1007/BF02532251 DOI: https://doi.org/10.1007/BF02532251
Bhatia M, Gorter A. Improving access to reproductive and child health services in developing countries: are competitive voucher schemes an option? Journal of International Development: The Journal of the Development Studies Association 2007; 19(7): 975-981. https://doi.org/10.1002/jid.1361 DOI: https://doi.org/10.1002/jid.1361
Dakin H, Wordsworth S. Cost-minimisation analysis versus cost-effectiveness analysis, revisited. Health Economics 2013; 19(2): 69-79. https://doi.org/10.1002/hec.1812 DOI: https://doi.org/10.1002/hec.1812
Ensor T, Cooper S. Overcoming barriers to health service access: influencing the demand side. Health Policy and Planning 2004; 19(2): 69-79. https://doi.org/10.1093/heapol/czh009 DOI: https://doi.org/10.1093/heapol/czh009
Filmer D, Scott K. Assessing asset indices. The World Bank., 2008. https://doi.org/10.1596/1813-9450-4605 DOI: https://doi.org/10.1596/1813-9450-4605
Willan AR, Lin D. Incremental net benefit in randomized clinical trials. Statistics in Medicine 2001; 20: 1563-1574. https://doi.org/10.1002/sim.789 DOI: https://doi.org/10.1002/sim.789
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Policy for Journals/Articles with Open Access
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work
Policy for Journals / Manuscript with Paid Access
Authors who publish with this journal agree to the following terms:
- Publisher retain copyright .
- Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work .
